Key result
Minimally invasive, video-assisted mitral valve repair in advanced Barlow's disease resulted in 0% hospital mortality and 100% freedom from ≥2+ mitral regurgitation at a median 761 days.
Why the study?
Is minimally invasive, video-assisted mitral valve repair safe and effective in patients with advanced Barlow's disease and bileaflet prolapse?
Observational (n=50)
Is minimally invasive, video-assisted mitral valve repair safe and effective in patients with advanced Barlow's disease and bileaflet prolapse?
Minimally invasive, video-assisted mitral valve repair is feasible and safe for complex advanced Barlow's disease with bileaflet prolapse, yielding excellent mid-term durability.
Supports minimally invasive repair in advanced Barlow's; hypothesis-generating, with randomized trials needed before practice change.
OBJECTIVES: Minimally invasive mitral valve (MV) surgery has recently gained popularity as the standard approach for MV repair, albeit there could be potential concerns about the feasibility of complex repair in the presence of extreme Barlow's disease via a minimally invasive route. METHODS: Fifty consecutive patients with advanced Barlow's disease and bileaflet prolapse underwent minimally invasive, video-assisted MV repair via a 5 cm right antero-lateral thoracotomy with peripheral cannulation and external aortic clamping. Mean age, left ventricular ejection fraction and New York Heart Association class were 53±11 years, 62±7% and 3.1±0.8, respectively. Logistic EuroSCORE (mean) was 3.1. Either Custodiol (36 patients; 72%) or crystalloid (14 patients; 28%) cardioplegia were utilized. Complete rings (CE Classic or Physio) were implanted. Chordal reimplantation was carried out by means of polytetrafluoroethylene (PTFE) chordae. RESULTS: All procedures were successfully performed with null/mild residual mitral regurgitation (MR) intraoperatively. A repair strategy of posterior leaflet resection and PTFE chordae implant (for anterior leaflet) or no-resect approach (only PTFE chordae on both leaflets) was performed in 62% (31 patients) and 38% (19 patients) of cases, respectively. Mean aortic cross-clamp and cardiopulmonary bypass times were 98±23 and 131±41 min, respectively. Hospital mortality was 0%. At a median follow-up of 761 days, 2 patients (4%) required reoperation (infective endocarditis: 1 patient; partial ring detachment: 1 patient) and valve rerepair was achieved in both. All patients are alive with a freedom from ≥2+ degree of MR of 100% at the latest echocardiographic evaluation. CONCLUSIONS: Minimally invasive approach for complex MV repair is feasible and safe and provided excellent early and mid-term results.
No takes yet. Share an insight, caveat, or question.
Muneretto et al. (2014) conducted an observational in Advanced Barlow's disease with bileaflet prolapse (n=50). Minimally invasive, video-assisted mitral valve repair was evaluated on Hospital mortality. Minimally invasive, video-assisted mitral valve repair in advanced Barlow's disease resulted in 0% hospital mortality and 100% freedom from ≥2+ mitral regurgitation at a median 761 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: